Clinical Practice | Published:

Beyond Tricyclics: New Ideas for Treating Patients With Painful and Refractory Functional Gastrointestinal Symptoms

The American Journal of Gastroenterology volume 104, pages 28972902 (2009) | Download Citation

Subjects

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    . Severe and refractory chronic abdominal pain: treatment strategies. Clin Gastroenterol Hepatol 2008; 6:978–82.

  2. 2.

    , , et al. Functional abdominal pain syndrome. In: Drossman DA, Corazziari E, Delvaux M (eds). Rome III: The Functional Gastrointestinal Disorders, 3rd edn. Degnon Associates: McLean, VA, 2006, pp 557–93.

  3. 3.

    , . Psychopharmacologic and behavioral treatments for functional gastrointestinal disorders. Gastrointest Endosc Clin N Am 2009; 19:151–70.

  4. 4.

    . The physician-patient relationship. In: Corazziari E (ed). Approach to the Patient With Chronic Gastrointestinal Disorders. Messaggi: Milan, Italy, 1999, pp 133–9.

  5. 5.

    , . Doctors Talking With Patients/Patients Talking With Doctors: Improving Communication in Medical Visits. Praeger: Westport, CT, 2006.

  6. 6.

    , , et al. Physician-patient communication: the relationship with malpractice claims among primary care physicians and surgeons. JAMA 1997; 277:553–9.

  7. 7.

    , , et al. Components of the placebo effect: randomised controlled trial in irritable bowel syndrome. Br Med J 2008; 336:999–1003.

  8. 8.

    , . Psychotropic agents in functional gastrointestinal disorders. Curr Opin Pharmacol 2008; 8:715–23.

  9. 9.

    , , et al. Psychosocial aspects of functional gastrointestinal disorders. In: Drossman DA, Corazziari E, Delvaux M (eds). Rome III: The Functional Gastrointestinal Disorders, 3rd edn. Degnon Associates: McLean, VA, 2006, pp 295–368.

  10. 10.

    , , et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367–78.

  11. 11.

    , , et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104:S1–7.

  12. 12.

    , , et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003; 124:303–17.

  13. 13.

    , , et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol 2009; e-pub ahead of print 18 April 2009.

  14. 14.

    , , et al. Cognitive-behavioral therapy versus education and desipramine verses placebo for moderate to severe functional bowel disorders. Gastroenterology 2003; 125:19–31.

  15. 15.

    , , et al. Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol 2005; 100:664–71.

  16. 16.

    , , et al. Not all side effects associated with tricyclic antidepressant therapy are true side effects. Clin Gastroenterol Hepatol 2009; 7:446–51.

  17. 17.

    . Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol 2008; 8:690–6.

  18. 18.

    , , et al. Amitriptyline reduces rectal pain-related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut 2005; 54:601–7.

  19. 19.

    , , . Cognitive role of neurogenesis in depression and antidepressant treatment. Neuroscientist 2008; 14:326–38.

  20. 20.

    . Does stress damage the brain? Biol Psychiatry 1999;45:797–805.

  21. 21.

    , , et al. Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. Bipolar Disord 2008; 10:1–37.

  22. 22.

    , , et al. Patients with pain disorder show gray-matter loss in pain-processing structures: a voxel-based morphometric study. Psychosom Med 2009; 71:49–56.

  23. 23.

    , , . A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008; 11:1169–80.

  24. 24.

    , , et al. Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr Serv 2008; 59:1121–30.

  25. 25.

    , , et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003; 361:653–61.

  26. 26.

    , , et al. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002; 123:1972–9.

  27. 27.

    , . Serotonin and neuroprotection in functional bowel disorders. Neurogastroenterol Motil 2007; 19:19–24.

  28. 28.

    , , et al. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol 2007; 5:1126–39.

  29. 29.

    , , et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006; 9:1–39.

  30. 30.

    , , et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354:1243–52.

  31. 31.

    , , et al. Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry 2004; 61:34–41.

  32. 32.

    , , et al. A multifaceted intervention to improve treatment of depression in primary care. Arch Gen Psychiatry 1996;53:924–32.

  33. 33.

    , , et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000; 342:1462–70.

  34. 34.

    , , et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997; 54:1009–15.

  35. 35.

    , , et al. Combination of antidepressants and psychological treatments for bulimia nervosa: a systematic review. Acta Psychiatr Scand 2000; 101:256–64.

  36. 36.

    , , et al. Management of chronic tension-type headache with tricyclic antidepressant medication, stress management therapy, and their combination. JAMA 2001; 285:2208–15.

  37. 37.

    , , et al. Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol 2003; 1:211–8.

  38. 38.

    , , et al. Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders. Dig Dis Sci 2009; 54:1284–91.

  39. 39.

    , , . Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psychopharmacol 2007; 22:1–9.

  40. 40.

    , , et al. The effect of gabapentin on neuropathic pain. Clin J Pain 1997; 13:251–5.

  41. 41.

    , . The serotonin syndrome. N Engl J Med 2005; 352:1112–20.

Download references

Author information

Affiliations

  1. Division of Gastroenterology and Hepatology, University of North Carolina Center for Functional GI and Motility Disorders, Chapel Hill, North Carolina, USA

    • Douglas A Drossman

Authors

  1. Search for Douglas A Drossman in:

Corresponding author

Correspondence to Douglas A Drossman.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/ajg.2009.341

Further reading